Smith MR et al., 2022-03-24: ARASENS added darolutamide or placebo to androgen deprivation plus docetaxel in 1,306 men with metastatic hormone-sensitive prostate cancer. Overall survival at 4 years was 62.7% vs 50.4% (HR 0.68), with similar rates of grade 3-4 adverse events (66.1% vs 63.5%).
the risk of death was significantly lower, by 32.5%, in the darolutamide group than in the placebo group (hazard ratio 0.68; 95% confidence interval, 0.57 to 0.80; P<0.001).
Abstract (RESULTS)
Smith MR et al., 2022-03-24: ARASENS added darolutamide or placebo to androgen deprivation plus docetaxel in 1,306 men with metastatic hormone-sensitive prostate cancer. Overall survival at 4 years was 62.7% vs 50.4% (HR 0.68), with similar rates of grade 3-4 adverse events (66.1% vs 63.5%). Funder: 'Funded by Bayer and Orion Pharma'. Conflicts: NEJM disclosure forms referenced, not printed; several authors disclose Bayer/Orion roles in the full text. Maker: Bayer (Nubeqa/darolutamide) with Orion. Comparator: matching placebo on top of ADT plus docetaxel – i.e. docetaxel is the backbone in both arms, so this trial tests triplet therapy, not docetaxel itself. Study type: randomized trial.
